India Launches First Zero Cost EMI for CAR-T Cell Therapy

In a significant advancement for cancer treatment accessibility, Immuneel and Arogya Finance have introduced India's first zero cost EMI programme for Qartemi® CAR-T Cell Therapy. This innovative financing solution allows patients to access treatment costs up to ₹25 lakh without any interest burden, making it easier for many to afford life-saving therapies. The zero cost EMI scheme aims to reduce the financial pressure on patients requiring CAR-T therapy, which is a cutting-edge treatment for specific blood cancers. Patients can choose flexible repayment terms that align with their financial situations, facilitating easier management of treatment costs. To qualify for this EMI option, patients must meet certain eligibility criteria established by Arogya Finance. Interested individuals can apply through Arogya Finance's official website or via selected healthcare partners. The application process is designed to be straightforward, ensuring quick approvals that allow for timely access to essential treatments. This initiative is expected to greatly benefit patients who have struggled to afford advanced cancer therapies in the past. By eliminating the financial barriers, Immuneel and Arogya Finance aim to improve the patient experience and encourage more individuals to seek timely medical intervention. Healthcare experts have praised this initiative, highlighting that financial constraints often delay critical treatments. Dr. Ramesh Kumar, a prominent oncologist, remarked, "This EMI programme is a crucial step towards making lifesaving treatments accessible to a broader population. It reflects a growing awareness of the need for affordable healthcare solutions in India." As the healthcare landscape in India continues to evolve, initiatives like the zero cost EMI for Qartemi CAR-T therapy could inspire similar financing options for various medical treatments. The collaboration between Immuneel and Arogya Finance may motivate other companies to explore innovative solutions that prioritize patient welfare. The launch of India's first zero cost EMI programme for Qartemi CAR-T Cell Therapy represents a major milestone in making advanced cancer treatment more accessible. This initiative not only provides financial relief but also highlights the importance of innovative healthcare financing in enhancing patient outcomes. Based on reports from Google News — Finance India.